Search

Your search keyword '"Young-Joo Cho, MD, PhD"' showing total 4 results
Start Over Author "Young-Joo Cho, MD, PhD"
4 results on '"Young-Joo Cho, MD, PhD"'

1. Effect of biologic therapies on quality of life in severe asthma: Findings from the PRISM study

Author

Hyo-In Rhyou, MD, PhD, Hyun-Kyoung Kim, MPH, Woo-Jung Song, MD, PhD, Sang Min Lee, MD, PhD, Sang-Ha Kim, MD, PhD, Jae-Woo Kwon, MD, PhD, Han-Ki Park, MD, PhD, Hye-Kyung Park, MD, PhD, Sang Hoon Kim, MD, PhD, Jeong-Hee Choi, MD, PhD, Sujeong Kim, MD, PhD, So-Young Park, MD, PhD, Sae-Hoon Kim, MD, PhD, Ji-Yong Moon, MD, PhD, Jae-Woo Jung, MD, PhD, Young-Joo Cho, MD, PhD, Chan Sun Park, MD, PhD, Byung Keun Kim, MD, PhD, Joo-Hee Kim, MD, PhD, Min-Suk Yang, MD, PhD, Min-Hye Kim, MD, PhD, Young-Hee Nam, MD, PhD, Taehoon Lee, MD, PhD, Byung-Jae Lee, MD, PhD, Pankaj Bhavsar, PhD, Ian M. Adcock, PhD, Kian Fan Chung, MD, DSc, and Tae-Bum Kim, MD, PhD

Subjects
Severe asthma, Quality of life, Biologics, Anti-IL-5, Anti-IL-4/IL-13, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Anti-type 2 (T2) biologic therapies (biologics) improve exacerbation rates, lung function, and asthma-related quality of life (QoL) in patients with severe T2 asthma. However, studies comparing different biologics are lacking. We evaluated the QoL in patients with severe asthma comprehensively and compare the efficacy of different T2-directed biologics using QoL questionnaires. Methods: We compared the QoL between severe and mild-to-moderate asthma and between severe asthma with and without biologics treatment. Data of mild-to-moderate were extracted from the Cohort for Reality and Evolution of Adult Asthma in Korea, and data of severe asthma were collected from the Precision Medicine Intervention in Severe Asthma. We included 183 patients with severe asthma treated with T2 biologics or conventional therapy between April 2020 and May 2021 and assessed QoL of them using the Questionnaire for Adult Korean Asthmatics (QLQAKA), Severe Asthma Questionnaire (SAQ), and EuroQoL-5Dimensions (EQ-5D) at baseline and 6 months. Results: The EQ-5D index (0.803) of severe asthma was lower than that of other chronic diseases representing a worse QoL. The scores for all questions of QLQAKA, except “cough,” were lower (less control) in the severe asthma group than in the mild-to-moderate asthma group at baseline and 6 months (P 0.05). Conclusion: QoL was worse in severe asthma than in mild-to-moderate asthma and other chronic diseases. T2 biologics equally improved QoL in patients with severe asthma.

Published
2024
Full Text
View/download PDF

2. A comparison of treatment response to biologics in asthma-COPD overlap and pure asthma: Findings from the PRISM study

Author

Ji-Su Shim, MD, PhD, Hyunkyoung Kim, MS, Jae-Woo Kwon, MD, PhD, So-Young Park, MD, PhD, Sujeong Kim, MD, PhD, Byung-Keun Kim, MD, PhD, Young-Hee Nam, MD, PhD, Min-Suk Yang, MD, PhD, Mi-Yeong Kim, MD, PhD, Sae-Hoon Kim, MD, PhD, Byung-Jae Lee, MD, PhD, Taehoon Lee, MD, PhD, Sang-Ha Kim, MD, PhD, So Young Park, MD, PhD, Young-Joo Cho, MD, PhD, Chan Sun Park, MD, PhD, Jae-Woo Jung, MD, PhD, Han-Ki Park, MD, PhD, Joo-Hee Kim, MD, PhD, Jeong-Hee Choi, MD, PhD, Ji-Yong Moon, MD, PhD, Ian Adcock, MD, PhD, Kian Fan Chung, MD, PhD, Min-Hye Kim, MD, PhD, and Tae-Bum Kim, MD, PhD

Subjects
Asthma-COPD overlap, Asthma, Biologics, Monoclonal antibodies, Treatment response, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Despite the increasing use of biologics in severe asthma, there is limited research on their use in asthma-chronic obstructive pulmonary disease overlap (ACO). We compared real-world treatment responses to biologics in ACO and asthma. Methods: We conducted a multicenter, retrospective, cohort study using data from the Precision Medicine Intervention in Severe Asthma (PRISM). ACO was defined as post-bronchodilator forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) 10 pack-years. Physicians selected biologics (omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab) based on each United States Food & Drug Administration (FDA) approval criteria. Results: After six-month treatment with biologics, both patients with ACO (N = 13) and asthma (N = 81) showed positive responses in FEV1 (10.69 ± 17.17 vs. 11.25 ± 12.87 %, P = 0.652), Asthma Control Test score (3.33 ± 5.47 vs. 5.39 ± 5.42, P = 0.290), oral corticosteroid use (−117.50 ± 94.38 vs. −115.06 ± 456.85 mg, P = 0.688), fractional exhaled nitric oxide levels (−18.62 ± 24.68 vs. −14.66 ± 45.35 ppb, P = 0.415), sputum eosinophils (−3.40 ± 10.60 vs. −14.48 ± 24.01 %, P = 0.065), blood eosinophils (−36.47 ± 517.02 vs. −363.22 ± 1294.59, P = 0.013), and exacerbation frequency (−3.07 ± 4.42 vs. −3.19 ± 5.11, P = 0.943). The odds ratio for exacerbation and time-to-first exacerbation showed no significant difference after full adjustments, and subgroup analysis according to biologic type was also showed similar results. Conclusions: Biologics treatment response patterns in patients with ACO and asthma were comparable, suggesting that biologics should be actively considered for ACO patients as well.

Published
2023
Full Text
View/download PDF

3. Epidemiology of patients with asthma in Korea: Analysis of the NHISS database 2006–2015

Author

Jung-Hyun Kim, MD, PhD, Hyesung Lee, PhD, So-Young Park, MD, PhD, Ju-Young Kim, MD, Sun Hee Choi, MD, PhD, Hyouk-Soo Kwon, MD, PhD, Woo-Jung Song, MD, PhD, Sae-Hoon Kim, MD, PhD, Jinho Yu, MD, PhD, Dae Jin Song, MD, PhD, You Sook Cho, MD, PhD, Dae Hyun Lim, MD, PhD, Young-Joo Cho, MD, PhD, Suk-Il Chang, MD, PhD, and Tae-Bum Kim, MD, PhD

Subjects
Asthma, Claims data, Severity, Immunologic diseases. Allergy, RC581-607
Abstract

Background: There has been a concerning increase in the prevalence and socioeconomic burden of asthma in Korea. Korea's National Health Insurance System (NHIS) covers insurance payment and claims management for all Koreans. Using National Health Insurance Sharing Service (NHISS) claims data. This study aimed to investigate patterns of healthcare utilization and direct cost in patients with asthma over a 10-year period. Methods: In this retrospective population-based study, we examined NHISS claims records between July 2005 and June 2016 and investigated healthcare utilization among patients with asthma based on age group and severity of disease (non-severe asthma [NSA] and severe asthma [SA]). Results: From 2006 to 2015, the total number of patients with asthma in Korea steadily increased from 743 968 to 2 286 309, with a corresponding increase in prevalence from 1.62% to 4.74%. The proportion of patients with SA decreased from 3.16% in 2006 to 1.56% in 2015; the proportion was consistently higher in men than in women. In addition, patients with SA had a higher cost per outpatient visit than patients with NSA, and the number of outpatient visits per year increased. The inhaled corticosteroid (ICS) prescription rate among patients with asthma decreased from 22.9% in 2006 to 15.7% in 2015. Furthermore, for a period of 10 years, more than 40% of patients with SA have been prescribed short-acting β-2 agonists (SABAs). Conclusions: Although patients with SA comprised a small proportion of patients with asthma, they incurred greater medical costs per person. The pharmaceutical prescription pattern indicated a lack of ICS-based prescriptions and frequent SABA prescriptions.

Published
2023
Full Text
View/download PDF

4. Clinical predictors of treatment response to tiotropium add-on therapy in adult asthmatic patients: From multicenter real-world cohort data in Korea

Author

Ji-Su Shim, MD, PhD, Juhae Jin, MA, Sae-Hoon Kim, MD, PhD, Taehoon Lee, MD, PhD, An-Soo Jang, MD, PhD, Chan Sun Park, MD, PhD, Jae-Woo Jung, MD, PhD, Jae-Woo Kwon, MD, PhD, Ji-Yong Moon, MD, PhD, Min-Suk Yang, MD, PhD, Jaechun Lee, MD, PhD, Jeong-Hee Choi, MD, PhD, Yoo Seob Shin, MD, PhD, Hee-Kyoo Kim, MD, PhD, Sujeong Kim, MD, PhD, Joo-Hee Kim, MD, PhD, Sang-Heon Cho, MD, PhD, Young-Hee Nam, MD, PhD, Sang-Hoon Kim, MD, PhD, So Young Park, MD, PhD, Gyu Young Hur, MD, PhD, Sang-Ha Kim, MD, PhD, Hye-Kyung Park, MD, PhD, Hyun Jung Jin, MD, PhD, Jae-Hyun Lee, MD, PhD, Jung-Won Park, MD, PhD, Ho Joo Yoon, MD, PhD, Byoung Whui Choi, MD, PhD, Young-Joo Cho, MD, PhD, Min-Hye Kim, MD, PhD, and Tae-Bum Kim, MD, PhD

Subjects
Tiotropium, Muscarinic antagonists, Asthma, Treatment response, Predictor, Immunologic diseases. Allergy, RC581-607
Abstract

Background: Tiotropium, a long-acting muscarinic antagonist, is recommended for add-on therapy to inhaled corticosteroids (ICS)-long-acting beta 2 agonists (LABA) for severe asthma. However, real-world studies on the predictors of response to tiotropium are limited. We investigated the real-world use of tiotropium in asthmatic adult patients in Korea and we identified predictors of positive response to tiotropium add-on. Methods: We performed a multicenter, retrospective, cohort study using data from the Cohort for Reality and Evolution of Adult Asthma in Korea (COREA). We enrolled asthmatic participants who took ICS-LABA with at least 2 consecutive lung function tests at 3-month intervals. We compared tiotropium users and non-users, as well as tiotropium responders and non-responders to predict positive responses to tiotropium, defined as 1) increase in forced expiratory volume in 1 s (FEV1) ≥ 10% or 100 mL; and 2) increase in asthma control test (ACT) score ≥3 after 3 months of treatment. Results: The study included 413 tiotropium users and 1756 tiotropium non-users. Tiotropium users had low baseline lung function and high exacerbation rate, suggesting more severe asthma. Clinical predictors for positive response to tiotropium add-on were 1) positive bronchodilator response (BDR) [odds ratio (OR) = 6.8, 95% confidence interval (CI): 1.6–47.4, P = 0.021] for FEV1 responders; 2) doctor-diagnosed asthma-chronic obstructive pulmonary disease overlap (ACO) [OR = 12.6, 95% CI: 1.8–161.5, P = 0.024], and 3) initial ACT score

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results